Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Simcha Therapeutics has raised $40.0M in total funding. The most recent round was Series B. The last funding was announced in January 2022.
Simcha Therapeutics's investors include HSG, Connecticut Innovations, Samsara BioCapital, Rock Springs Capital, SR One.
Simcha Therapeutics is headquartered in New Haven, United States.
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Simcha Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Simcha Therapeutics — Funding & Investors." VCBacked, January 27, 2022, https://www.vcbacked.co/company/simcha-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Simcha Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/simcha-therapeutics
{{cite web |title=Simcha Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/simcha-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated